Softgel Technology: A Game-Changer For Oncology Treatment

Douglas, a New Zealand-based pharmaceutical company and CDMO, is recognized for its specialization in high-potency softgel and liquid formulations. With a focus on oncology treatments, the company has built a strong reputation in the US and internationally for its softgel technology. Softgels offer numerous advantages, including a gelatin outer shell that enables rapid release and immediate drug absorption in the gastrointestinal tract. This is particularly beneficial for high-potency oncology drugs, where timely delivery and precise dosing are essential for maximizing efficacy.

Douglas's expertise in self-emulsifying drug delivery systems (SEDDS) ensures even distribution of active pharmaceutical ingredients (APIs) within the softgel, enhancing bioavailability and consistency in drug absorption. The company also develops controlled-release formulations to provide sustained drug delivery, reducing side effects and improving patient compliance. Softgel technology also protects sensitive APIs from degradation, ensuring drug stability throughout its shelf-life.

With decades of innovation, Douglas continues to refine its softgel formulations to improve cancer treatment outcomes.

Discover how Douglas is advancing oncology therapies through cutting-edge softgel technology.